Twist Bioscience Corporation (TWST) Aandelenanalyse

Bedrijfsoverzicht

Twist Bioscience Corporation is a specialized manufacturer dedicated to the production and sale of synthetic DNA-based products, a core capability that supports extensive product development across therapeutics, diagnostics, chemicals, food, agriculture, and academic research sectors. The company operates within the Healthcare sector, specifically targeting the Diagnostics & Research industry, which positions it as a critical enabler for pharmaceutical innovation and scientific discovery rather than a direct provider of consumer goods. At present, the entity manages a workforce of 979 employees and maintains a total market capitalization of $2.94B, while generating annual revenue of $391.56M over the trailing twelve months. These valuation and revenue figures indicate that the market assigns a significant premium to the company's intellectual property and synthetic biology platform, reflecting high expectations for future commercialization despite the current lack of profitability. The scale of the operation, evidenced by nearly $400 million in revenue, suggests that Twist has successfully transitioned from a research-focused entity to a commercial player with substantial operational footprint.

Financiële gezondheid

Twist Bioscience reported trailing twelve-month revenue of $391.56M, yet this top-line activity resulted in a net income of -$76.58M and an EBITDA of -$112.75M, highlighting a substantial gap between revenue generation and bottom-line profitability. This disparity between revenue and net income reveals a cost structure where expenses related to research and development, manufacturing scaling, or general administration currently exceed the gross profits generated from sales. The company's free cash flow stands at -$47.24M, indicating a net cash outflow that limits immediate financial flexibility for large-scale capital expenditures or aggressive share buybacks without external financing. Despite the negative cash flow, the balance sheet retains a robust cash reserve of $197.95M, which provides a significant buffer against operational burn and potential market downturns. The company carries total debt of $113.05M, resulting in a debt-to-equity ratio of 24.79, while maintaining a current ratio of 3.78 that signals strong short-term liquidity and an ability to cover current obligations well over three times. Return on Equity is recorded at -16.8% and Return on Assets at -13.5%, metrics that explicitly reveal that management has not yet achieved positive capital efficiency or generated returns sufficient to cover the cost of equity and debt capital employed.

Waarderingsbeoordeling

The trailing twelve-month P/E ratio is not available due to negative earnings, whereas the forward P/E is listed at -25.42, a figure that implies the market is pricing in a significant earnings recovery trajectory or is valuing the company primarily on growth potential rather than current cash earnings. The price-to-book ratio sits at 6.44, suggesting that the market values the company at more than six times its net asset value, which indicates a substantial premium assigned to the company's intangible assets, such as patents and proprietary synthetic biology technology. Alternative valuation metrics like the price-to-sales ratio of 7.50 and an EV/EBITDA of -25.30 further suggest that traditional multiple-based comparisons are less relevant for a company in this pre-profitability phase, with valuation driven by sales scale and growth expectations rather than earnings multiples. Over the past year, the stock price fluctuated between a 52-week low of $23.30 and a high of $57.88, meaning the current trading price sits at a specific point within this range relative to recent volatility. The beta value of 2.21 indicates that the stock's price volatility is more than twice as high as that of the broader market, reflecting the heightened risk profile associated with biotechnology development and regulatory approval timelines.

Growth & Income

Revenue growth year-over-year stands at 16.9%, demonstrating a consistent expansion in sales volume, while earnings growth is marked as N/A due to the company's persistent net losses, implying that top-line growth is currently decoupled from bottom-line profitability. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are effectively reinvested into research and development, manufacturing capacity, and strategic acquisitions to fuel long-term expansion rather than providing immediate income to shareholders. This reinvestment strategy is typical for biotechnology firms that prioritize scaling their synthetic DNA platform and securing regulatory approvals over returning capital to investors in the short term. The overall growth and income profile of Twist Bioscience is characterized by strong sales expansion coupled with a lack of current dividend income, relying entirely on capital markets or internal cash reserves to fund operations and future commercial milestones.